Man Group
SEEL

Man Group’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

Man Group’s Portfolio SEEL Stock Details SEEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-3
Closed -$13K – 2288
2022
Q3 		$13K Buy
+3
New +$11.8K ﹤0.01% 1962
2022
Q2 		– Hold
0
– – – 1999

Other funds holding SEEL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
MWM
Modera Wealth Management Westwood, New Jersey $8.34B AUM 19.68% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

Man Group's SEEL Position: Q4 2022 in Review

Man Group sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q4 2022, closing a stake of 3 shares — an estimated $13K sold.

Man Group first reported a position in SEEL in Q3 2022 and held it in 1 quarter. The position peaked at $13K in Q3 2022. 63 funds tracked by Wall St. Rank hold SEEL as of Q4 2022.

  • Man Group reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Man Group sold 3 Seelos Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $13K.
  • Man Group first reported a position in Seelos Therapeutics, Inc. Common Stock in Q3 2022 and held it in 1 quarter.
  • Man Group's Seelos Therapeutics, Inc. Common Stock position peaked at $13K in Q3 2022.
  • 63 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Man Group's 13F filing for Q4 2022, filed 14 Feb 2023.